Chris Langmead is Head of the Servier Drug Discovery Program at the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University, a collaborative and multidisciplinary discovery program targeting GPCRs across a range of therapeutic indications.
Prior to this he was Head of Pharmacology at Heptares Therapeutics Ltd., a UK-based biotechnology company (2009-2012). He was responsible all of the company’s in vitro and in vivo pharmacology, ADME/PK and toxicology (in house and outsourced). He is an acknowledged expert in GPCR drug discovery and analytical receptor pharmacology, and has led projects for Parkinson’s, ADHD, schizophrenia, sleep disorders and Alzheimer’s disease into late stage preclinical development, many of which are now in clinical development. Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009).
He has a degree and PhD in pharmacology from Queens' College, Cambridge and University College London, respectively, is a corresponding member of NC-IUPHAR and a Fellow of the British Pharmacological Society. Chris holds both commercial and NHMRC funding and serves on the editorial boards of the British Journal of Pharmacology, ACS Chemical Neuroscience, ACS Pharmacology & Translational Science and Frontiers in Pharmacology.